Hi @dachopper
Agree entirely with your Post #: 68575207 . Surrogate endpoints can be alluring (sometimes for the wrong reasons).
And if one were to ask 'why the focus on LVAD in CHF?', you could be excused for looking no further than that existing orphan drug designation.
We should all be aware that the ability to manage the cost of powering of trials, obtain time-shortening designations & also obtain 'moat' maximising designations is worth huge money in global biotech.
It is an enduring tribute to the MSB Board & management IMO that MSB has been able to wrangle the current portfolio of Ph III indications & supporting data to where it is on what is, effectively, a shoestring.
Show me one biotech in the US or AU that has produced a better Ph III portfolio with such constrained resources.
Cheers all.
Hi @dachopperAgree entirely with your Post #: 68575207 ....
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
-0.005(0.42%) |
Mkt cap ! $1.341B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.20 | $1.14 | $10.44M | 8.934M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 45750 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 1476 | 1 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.18 |
Change
-0.005 ( 0.31 %) |
||||
| Open | High | Low | Volume | ||
| $1.18 | $1.20 | $1.14 | 1465927 | ||
| Last updated 15.59pm 24/05/2024 ? | |||||
| MSB (ASX) Chart |